TLSI Earnings & Financial Statements
TriSalus Life Sciences, Inc.
$4.06
-$0.07(-1.69%)
33
Overall
40
Value
10
Tech
50
Quality
Market Cap
$249.99M
Volume
198.96K
52W Range
$2.20 - $7.95
Target Price
$10.40
TLSI earnings and financial statements: TriSalus Life Sciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TLSI Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $45.15M | $29.43M | $18.51M | $12.40M | - |
| Cost of revenue | $6.96M | $4.10M | $2.60M | $2.26M | $1.19M |
| Operating income | -$26.95M | -$36.16M | -$54.48M | -$36.44M | -$3.04M |
| EBITDA | -$31.57M | -$25.33M | -$58.45M | -$46.78M | -$26.62M |
| Net income | -$39.23M | -$30.05M | -$59.36M | -$47.19M | -$28.84M |
| EPS (diluted) | $-1.84 | $-1.31 | $-6.73 | $0.19 | $0.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $35.33M | $23.97M | $24.60M | $22.00M | $250.53M |
| Total liabilities | $69.19M | $49.87M | $51.66M | $34.32M | $17.25M |
| Shareholders’ equity | -$33.86M | -$25.89M | -$27.07M | -$176.33M | -$16.72M |
| Cash and equivalents | $20.44M | $8.53M | $11.78M | $9.41M | $200.9K |
| Long-term debt | $33.05M | $22.08M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.01M | -$40.84M | -$50.58M | -$32.31M | -$22.70M |
| Capital expenditure | -$838.0K | -$345.0K | -$588.0K | -$786.0K | -$1.26M |
| Free cash flow | -$18.93M | -$41.19M | -$51.17M | -$33.10M | -$23.95M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TLSI | $4.06 | -1.7% | 198.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get TriSalus Life Sciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW